Skip to main
  1. Stocks
  2. Stryker
  3. Forecast
SYK

Stryker (SYK) Stock Forecast & Price Target

Stryker (SYK) Analyst Ratings

Based on 19 analyst ratings
Buy
Strong Buy 26%
Buy 53%
Hold 21%
Sell 0%
Strong Sell 0%

Bulls say

Stryker is well positioned to sustain high-single-digit to low-double-digit organic sales growth because its MedSurg, Endoscopy, Medical, and Vascular franchises all showed healthy demand, with 9.1% organic MedSurg growth, $1.02 billion of Endoscopy revenue, and $60 million of Vascular outperformance. Its outlook is also strengthened by market leadership in orthopedic robotics and operating room equipment, plus a disciplined innovation pipeline that includes the 1888 platform, Neptune due in 1H27, and potential Vascular commercialization in 2027. Financially, the company is supporting growth with robust cash generation, a $1 billion 3Q buyback and new $3 billion authorization, while the $400 million CMR Surgical investment expands soft-tissue robotics without heavy upfront R&D risk.

Bears say

Stryker is facing a more cautious fundamental backdrop as 3Q revenue of $6.52 billion and adjusted EPS of $3.52 both missed expectations, while FY2026 organic growth guidance was cut to 6.5%-7.0% from 8.3%-9.3%. The main weakness is concentrated in orthopedics, where hips and knees were flat year over year and management cited a softer market growing about 2.5%, slower launch uptake, prior-authorization friction, and execution disruptions tied to cyberattack-related pressures and an SAP transition. Although margins held up with gross margin at 65.4% and operating margin at 26.2%, the combination of lower growth expectations, lingering vascular supply issues, and slower share gains suggests the business is no longer compounding as consistently as before.

Stryker (SYK) has been analyzed by 19 analysts, with a consensus rating of Buy. 26% of analysts recommend a Strong Buy, 53% recommend Buy, 21% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Stryker and is not a guaranteed prediction by Public.com or investment advice.

Stryker (SYK) Analyst Forecast & Price Prediction

Get the latest Stryker (SYK) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Stryker (SYK)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Stryker (SYK) Forecast

Analysts have given Stryker (SYK) a Buy based on their latest research and market trends.

According to 19 analysts, Stryker (SYK) has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $353.95, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $353.95, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Stryker (SYK)


Stryker (SYK) Analyst Forecast & Price Prediction

Get the latest Stryker (SYK) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Stryker (SYK)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover SYK stock data and trends